<DOC>
	<DOC>NCT00834080</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of Medisorb速 naltrexone (VIVITROL速) when administered over a period of 24 months to health care professionals who have a history of opioid dependence.</brief_summary>
	<brief_title>ALK21-021: A Safety Study of Medisorb速 Naltrexone (VIVITROL速) Administered to Health Care Professionals</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Health care professional (eg, physician, osteopath, nurse, pharmacist) 18 years of age or older Enrolled or enrolling in an extended outpatient treatment program for opioid dependence Women of childbearing potential must agree to use an approved method of contraception for the duration of the study Primary Pregnancy and/or lactation Evidence of hepatic failure Active hepatitis Any psychiatric disorder that would compromise ability to complete study requirements Recent history of suicidal ideation or attempt Current dependence to any drugs other than prescription opioids or heroin, benzodiazepines, caffeine, marijuana, alcohol, or nicotine Positive urine drug test or selfreported use of opioids, cocaine, or amphetamines at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>opioid dependence</keyword>
	<keyword>VIVITROL</keyword>
	<keyword>opioid-related disorders</keyword>
</DOC>